P-Values

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance. 

Featured

Blog Post

Global Health Watch: Hepatitis B vaccine trial halted, HIV advocates demand action, LEN for PrEP access, Global Fund’s malaria accelerator

International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.

Read more

Blog Post

No Time to Lose: Reaching At Least Three Million with LEN for PrEP by 2027

AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.

Read more

Blog Post

Global Health Watch: World Health Summit highlights, UN pandemic declaration, Guinea-Bissau vaccine trial, NIH peer-review changes

Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded hepatitis B vaccine trial in Guinea-Bissau, and proposed changes to NIH’s scientific peer-review process raise new questions about transparency and political influence over research funding.

Read more

Filter by

Reset filters

P-Values

showing 1-10 of 1275

Global Health Watch: Hepatitis B vaccine trial halted, HIV advocates demand action, LEN for PrEP access, Global Fund’s malaria accelerator

International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.

October 2026

No Time to Lose: Reaching At Least Three Million with LEN for PrEP by 2027

AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.

Prevention Option:

Topic:

October 2026

Global Health Watch: World Health Summit highlights, UN pandemic declaration, Guinea-Bissau vaccine trial, NIH peer-review changes

Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded hepatitis B vaccine trial in Guinea-Bissau, and proposed changes to NIH’s scientific peer-review process raise new questions about transparency and political influence over research funding.

Topic:

October 2026

Global Health Watch: NIH Orders Pause on HIV Trials, Zimbabwe + Zambia Health MoUs, WHO + Global Fund leadership, Foreign Assistance Funds

The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be complete by November 30, 2027, when their current funding is set to expire.” This potentially devastating development comes as new questions emerge about how billions in US foreign assistance funding were spent, and details on the impacts of an end of US health assistance to Zimbabwe emerge. Also, a new candidate for WHO leadership and growing civil society calls to protect UNAIDS.

Topic:

October 2026

The Latest Resources from AVAC: The Power of Coalition Advocacy

Advocacy has always been the heartbeat of progress in the fight against HIV/AIDS. Now, more than ever, it is especially needed to ensure that innovation translates into real choices, equitable access and meaningful impact. In this issue, we highlight the power of coalition advocacy – from advocates working in partnership to shape research agendas and oppose policies that threaten progress, to ensuring communities have a voice in AI development and use, to the lessons learned from sustained, coalition-based advocacy that will shape what comes next.

October 2026

Advocates Lead at AIDS 2026: Moving from a seat at the table to the head of the table  

The power and leadership of advocates were on full display at AIDS 2026. Following global funding cuts and concerns about de-prioritization of communities and civil society, advocates brought evidence of their impact and the value of continued investment in communities to Rio. On topics ranging from HIV prevention access to the future of artificial intelligence in HIV programs, advocates were driving conference discussions to ensure the community agenda was seen, heard and acted upon.

October 2026

Global Health Watch: Billions in Question, NIH + America First Plans, WHO + Global Fund Leadership & PPPR Rejection

The US fiscal year ended this week amid questions about the billion dollars in Congressionally-appropriated foreign assistance, while new strategies for HIV research at the National Institutes of Health (NIH) and the America First Global Health strategy theoretically move into implementation phases. Also, the Global Fund announced five candidates for its Executive Director, and six candidates were shared as possible leaders of the World Health Organization (WHO), just after the US rejected the UN pandemic preparedness declaration at the end of last week.

October 2026

Global Health Watch: White House Drops NIH Review Plan, NIAID Reorg Moves Fwd, Prep for Generic LEN Access, Accra Reset

There is no shortage of global health news this week. Against the backdrop of the UN General Assembly (UNGA 81), this issue covers efforts to reshape the global health architecture through the Accra Reset, proposed and withdrawn Executive Orders affecting NIH grant making, NIAID restructuring developments, and preparations to expand access to generic lenacapavir for PrEP.

September 2026

Global Health Watch: LEN Access Pathways, NIAID Reorganization, Global Fund Report, NIH Lawsuit

This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for greater transparency around a proposed NIAID restructuring, and a new lawsuit challenging NIH’s screening of research grants. With today as the final day to comment on the NIAID proposal, make your voice heard. And read on for a provocative Lancet commentary on the challenges of trying to reform global health architecture.

September 2026

All things alimatravir (AMI)

AVAC and partners have been engaging with Merck/MSD since the very start of the alimatravir product development program and helped conceptualize the EXPrESSIVE efficacy trial design. Building on this foundation of community-centricity, advocates can now push for AMI to be rolled out with speed, scale and equity. Since 2012, each successive PrEP introduction has gone faster than the previous one, yet the time to market and to public health impact for PrEP remains too slow. Read on for AVAC’s insights on AMI, from accelerated licensing and affordability to community priorities and meaningful engagement.

Prevention Option:

Topic:

September 2026

showing 1-10 of 1275

Explore More News and Communications

P-Values Blog

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

Advocates Network

AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.

Weekly News Digest

A comprehensive round-up of HIV prevention media coverage and scientific publications.

PxPulse

Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.

PxWire

PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.

Pandemic Watch

Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.

Press Releases

A collection of official statements from AVAC.

AVAC in the News

Media clippings featuring AVAC, its staff and close partners in the news media.